Research Publications

Outcome of acute ST-segment elevation myocardial infarction in diabetics treated with fibrinolytic or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: lessons from the GUSTO V trial.

Gurm HS, Lincoff AM, Lee D, Tang WH, Jia G, Booth JE, Califf RM, Ohman EM, Van de Werf F, Armstrong PW, Guetta V, Wilcox R, Topol EJ, GUSTO V Trial

Risk factors for intracranial hemorrhage and nonhemorrhagic stroke after fibrinolytic therapy (from the GUSTO-i trial).

Kandzari DE, Granger CB, Simoons ML, White HD, Simes J, Mahaffey KW, Gore J, Weaver WD, Longstreth WT Jr, Stebbins A, Lee KL, Califf RM, Topol EJ, Global Utilization of Streptokinase and tPA for Occluded Arteries-I Investigators

International differences in evolution of early discharge after acute myocardial infarction.

Kaul P, Newby LK, Fu Y, Mark DB, Califf RM, Topol EJ, Aylward P, Granger CB, Van de Werf F, Armstrong PW

Percutaneous coronary intervention in diabetic patients with non-ST-segment elevation acute coronary syndromes.

Roffi M, Topol EJ

Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events.

Ringleb PA, Bhatt DL, Hirsch AT, Topol EJ, Hacke W, Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events Investigators

Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes.

McGuire DK, Newby LK, Bhapkar MV, Moliterno DJ, Hochman JS, Klein WW, Weaver WD, Pfisterer M, Corbalán R, Dellborg M, Granger CB, Van De Werf F, Topol EJ, Califf RM, SYMPHONY and 2nd SYMPHONY Investigators

The combination of enoxaparin, glycoprotein IIb/IIIa inhibitors and an early invasive approach among acute coronary syndrome patients.

Lee DS, Bhatt DL, Moliterno DJ, Peacock WF, Ellis SG, Topol EJ

Premature myocardial infarction novel susceptibility locus on chromosome 1P34-36 identified by genomewide linkage analysis.

Wang Q, Rao S, Shen GQ, Li L, Moliterno DJ, Newby LK, Rogers WJ, Cannata R, Zirzow E, Elston RC, Topol EJ

Pathobiology of atherosclerosis: are there racial and ethnic differences?

Watson KE, Topol EJ

Triple antiplatelet therapy does not increase femoral access bleeding with vascular closure devices.

Exaire JE, Dauerman HL, Topol EJ, Blankenship JC, Wolski K, Raymond RE, Cohen EA, Moliterno DJ, TARGET Investigators